Navigation Links
Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
Date:7/9/2008

osis with a novel mechanism that may provide advantages over currently available therapies," said William R. Shanahan, M.D., Arena's Vice President and Chief Medical Officer. "We will review and evaluate the results with our consultants to develop the best approach to advance APD791 into Phase 2 clinical trials. We are also actively exploring partnership opportunities for this candidate."

"These positive results also demonstrate the utility of our focus on G protein-coupled receptor (GPCR) drug research and the general approach we take toward developing innovative treatments for serious medical conditions. Applying our GPCR focus and expertise, we've developed a pipeline of seven novel development stage drug candidates, five of which are in the clinic," stated Dominic P. Behan, Ph.D., Arena's Senior Vice President and Chief Scientific Officer.

About APD791

APD791 is a novel, oral and selective inverse agonist of the 5-HT2A serotonin receptor. Serotonin activation of the 5-HT2A receptor on platelets and vascular smooth muscle is thought to play an important role in events leading to thrombosis, and elevated serotonin levels have been associated with increased cardiovascular risk. Normally, when a platelet is activated by one of a number of factors, such as thrombin or collagen, the platelet releases serotonin, which, based on preclinical studies, promotes platelet aggregation, vasoconstriction and intimal hyperplasia. By blocking activation of the 5-HT2A receptor on platelets and other cardiovascular tissues, APD791 may curb these serotonin-mediated effects in the clinical setting, thereby reducing or preventing thrombosis. Furthermore, based upon preclinical studies, Arena believes that APD791, by preventing only the amplification of platelet aggregation induced by primary aggregators such as ADP and collagen, may allow sufficient platelet aggregation at therapeutic doses to avoid the bleeding risk associated with other anti-platelet agents whil
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
2. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
3. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
6. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
7. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
8. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
9. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
10. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
11. Isis Pharmaceuticals Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Aileron Therapeutics, Inc. - Product Pipeline ... Direct,s, ,Aileron Therapeutics, Inc. - Product Pipeline Review ... Therapeutics, Inc.,s pharmaceutical research and development focus. ... therapeutic developmental pipeline of Aileron Therapeutics, Inc.,s, complete ... by drug target, mechanism of action (MoA), route ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
(Date:9/30/2014)... NEW YORK , Sept. 30, 2014 ... stage. Growing ageing population and rise in the incidence ... of chronic wounds and in affordability of better quality ... Chinese wound care market. Universal coverage of public health ... products would further stimulate demand. Based on the findings ...
Breaking Medicine Technology:Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 2Aileron Therapeutics, Inc. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4China Wound Care Market 2China Wound Care Market 3
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
(Date:10/1/2014)... encourages people to keep their "eyes on the prize" ... When walking, staying focused on a specific target ahead ... help people walk there faster, psychology researchers have found. ... looking around the environment naturally, offers a new strategy ... less interested in exercise if physical activity seems daunting, ...
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... 01, 2014 Bedros Keuilian is not ... Camp fitness boot camps, he’s also considered the leading ... with sold out business summits, a line of high-demand ... to a recent Spike TV reality show to his ... is the time for personal trainers and fitness business ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 First Warning ... abnormal circadian cellular changes throughout the body, announced the ... to better address the company’s breadth of upcoming product ... breast cancer screening technology. , “Our initial focus will ... system which detects abnormal circadian cellular changes over time,” ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4
... MTBC also launches the PDA version of its ... MTBC, the unique revenue cycle,and practice management ... for patients with United Healthcare insurance.,MTBC believes it ... this,breakthrough with any insurer., RTA provides an ...
... very nature, skin of color is,considered sensitive skin by ... of skin problems. Acne and rosacea,can be especially problematic ... skin irritation in these patients can cause pigmentation,problems that ... skin., At the American Academy of Dermatology,s Summer ...
... Cord Blood, DETROIT, July 30 The Barbara ... multi-year grant,from the J.P. McCarthy Fund of the Community ... Stem Cell Bank. The grant, which,will be given in ... area and expand the capacity to help people in ...
... someday replace the invasive, uncomfortable endoscope now used ... esophagus. , Steven J. Ackerman of University of ... Glenn T. Furuta, his colleague at the University ... for an all-fronts attack on eosinophilic esophagitis, an ...
... Ltd. (Amex: CPD ) announced today, that ... behalf of Sun Pharmaceutical,Industries Ltd. (Sun Pharma). Sun ... Drug Administration (FDA) for its Abbreviated New Drug,Application ... Divalproex sodium delayed release tablets are indicated as ...
... FOX, ABC, NBC ... and CBS, ... the adventures of parenting, announced that "Viva la,Familia! de Todobebe" (Hooray for ... Friday night July 25th in Prime,Time delivering 3.3 million viewers 2+ and ...
Cached Medicine News:Health News:MTBC First Medical Billing Company in the U.S. To Offer Automated Real-time Adjudication of Claims 2Health News:American Academy of Dermatology: Acne and Rosacea Got You Seeing Red? Patients with Skin of Color Advised to Seek Proper Diagnosis, Treatment to Prevent Common Side Effects 2Health News:American Academy of Dermatology: Acne and Rosacea Got You Seeing Red? Patients with Skin of Color Advised to Seek Proper Diagnosis, Treatment to Prevent Common Side Effects 3Health News:American Academy of Dermatology: Acne and Rosacea Got You Seeing Red? Patients with Skin of Color Advised to Seek Proper Diagnosis, Treatment to Prevent Common Side Effects 4Health News:J.P. McCarthy Fund Grants $250,000 to Karmanos Cancer Institute 2Health News:J.P. McCarthy Fund Grants $250,000 to Karmanos Cancer Institute 3Health News:J.P. McCarthy Fund Grants $250,000 to Karmanos Cancer Institute 4Health News:String probes for devastating childhood digestive disease 2Health News:Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets 2Health News:Todobebe's New Family TV Show Debuts as #1 Show in the U.S. Among All Adults 18 to 34 2
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: